Prosecution Insights
Last updated: April 19, 2026
Application No. 18/390,368

WEE1 INHIBITORS AND USES THEREOF

Non-Final OA §112
Filed
Dec 20, 2023
Examiner
PIHONAK, SARAH
Art Unit
1627
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Boundless Bio Inc.
OA Round
1 (Non-Final)
61%
Grant Probability
Moderate
1-2
OA Rounds
2y 11m
To Grant
99%
With Interview

Examiner Intelligence

Grants 61% of resolved cases
61%
Career Allow Rate
900 granted / 1477 resolved
+0.9% vs TC avg
Strong +44% interview lift
Without
With
+43.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
47 currently pending
Career history
1524
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
39.9%
-0.1% vs TC avg
§102
11.0%
-29.0% vs TC avg
§112
20.5%
-19.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1477 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Priority This application, filed 12/20/2023 Claims Priority from Provisional Application 63476846 , filed 12/22/2022. Status of Claims Claims 1, 12, 14, 17, 19, 21, 25, 33-34, 36, 39-40, 47, 51, 54, 58, 60, and 117-119 are pending as of the claim set filed on 3/4/24. Claims 2-11, 13, 15-16, 18, 20, 22-24, 26-32, 35, 37-38, 41-46, 48-50, 52-53, 55-57, 59, 61-116, and 120-136 have been canceled. Claims 1, 12, 14, 17, 19, 21, 25, 33-34, 36, 39-40, 47, 51, 54, 58, 60, and 117-119 were examined. Claims 12, 14, and 17 are rejected. Claims 1, 19, 21, 25, 33-34, 36, 39-40, 47, 51, 54, 58, 60, and 117-119 are allowed. Claim Rejections-35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.— The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claims 12, 14, and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 12 depends directly from claim 1 and refers to variables R 9 and R 10 . However, claim 1 doesn’t recite these variables. From the claims, it is uncertain if R 9 and R 10 actually refer to a subset of R 8 of claim 1 or not. The claim is indefinite, as claim 12 lacks antecedent basis for R 9 and R 10 . Claims 14 and 17 are similarly rejected as these claims depend directly from claim 12 and don’t provide further clarity. Reasons for Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: the claimed compounds are not taught or suggested by the prior art . Xie et. al., WO 2022174796 A1, cited in the IDS, English equivalent US 20240158369 A1 ; and Xie et. al., WO 2022174765 A1, cited in the IDS (Xie 2 ; English equivalent US 20240182447 ) represent the closest prior art. Xie teaches inhibitors of Wee1 kinase of the following structural formula: . Xie teaches the proviso compound of claim 60, and compound s wherein ring A is a heteroaryl ring. However, the compounds of claim 60 differ by the lack of the -N=S=O(R 1 R 2 ) substituent on ring A, which is required by the compounds taught by Xie. Xie 2 teaches Wee1 kinase inhibitors that share several structural features with compounds of instant claim 1, including a pyrimidine ring bonded via an amine group to a pyridine ring. However, the position corresponding to ring A of Xie 2 is occupied by a tricyclic ring, while ring A of claim 1 must be a mono- or bicyclic ring. Information Disclosure Statement The IDS filed on 1/11/24 has been considered. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT SARAH PIHONAK whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-7710 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Monday-Friday 9:00-5:30 EST . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Kortney Klinkel can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 571-270-5239 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. FILLIN "Examiner Stamp" \* MERGEFORMAT SARAH . PIHONAK Primary Examiner Art Unit 1627 /SARAH PIHONAK/ Primary Examiner, Art Unit 1627
Read full office action

Prosecution Timeline

Dec 20, 2023
Application Filed
Mar 02, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599584
INDOLINE DERIVATIVES, COMPOSITIONS COMPRISING THEM AND USES THEREOF
2y 5m to grant Granted Apr 14, 2026
Patent 12594236
Method of Treating Acute Exacerbation of Schizophrenia with Long-Acting Injectable Depot Composition
2y 5m to grant Granted Apr 07, 2026
Patent 12594338
CISPLATIN ANALOGUE WITH POTENT ANTI-CANCER EFFECTS AND SYNTHESIS THEREOF
2y 5m to grant Granted Apr 07, 2026
Patent 12576047
TELOMERASE ACTIVATING COMPOUNDS FOR USE IN FERTILITY AND RELATED APPLICATIONS
2y 5m to grant Granted Mar 17, 2026
Patent 12577209
AMINO ACID COMPOSITIONS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
61%
Grant Probability
99%
With Interview (+43.7%)
2y 11m
Median Time to Grant
Low
PTA Risk
Based on 1477 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month